Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer
Pathology International · 2025-11 · 75 (11) · 551-561
DOI: 10.1111/pin.70062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology International, online erschienen am 12.11.2025. Verfasst von Yukio Fujiwara und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto, Japan. Hauptthemen laut MEDLINE: Neoplasms, Antigens, CD, Macrophages, Sialic Acid Binding Ig-like Lectin 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: This study was supported by the Japan Society for the Promotion of Science Program [Grant Numbers 20H03459 to Y.K. and 23K06362 to Y.F.] from the Japan Society….
Abstract (Originalsprache)
Macrophage activation markers, specifically CD163 and CD169, play pivotal roles in the modulation of immune responses within the tumor microenvironment (TME), influencing the outcome of various cancers. These markers delineate the activation states of macrophages, with CD163 associated with the protumoral phenotype and CD169 with activation of tumor immunity. This review comprehensively explores the dualistic roles of these markers in cancer progression and immune suppression, and discusses the mechanisms through which these markers influence macrophage behavior, the impact of their expression on cancer progression, and the therapeutic potential of targeting these pathways to reprogram the TME toward enhancing antitumor immunity. This review aims to underscore the therapeutic potential of macrophage activation markers as targets for cancer treatment, highlighting emerging strategies and future directions in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto, Japan.
- Center for Metabolic Regulation of Healthy Aging, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Yukio Fujiwara
Förderung
- This study was supported by the Japan Society for the Promotion of Science Program [Grant Numbers 20H03459 to Y.K. and 23K06362 to Y.F.] from the Japan Society…
Zitieren
APA
Fujiwara, Y., & Komohara, Y. (2025). Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer. Pathology International, 75(11), 551-561. https://doi.org/10.1111/pin.70062
Vancouver
Fujiwara Y, Komohara Y. Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer. Pathology International. 2025;75(11):551-561. doi:10.1111/pin.70062
BibTeX
@article{Fujiwara2025,
author = {Fujiwara, Yukio and Komohara, Yoshihiro},
title = {Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer},
journal = {Pathology International},
year = {2025},
volume = {75},
number = {11},
pages = {551--561},
doi = {10.1111/pin.70062}
}
EUVIMED